ClinicalTrials.gg
Not yet recruitingNCT07696182VOYAGER CEUpdated Nov 12, 2026

Validation Of anatomY-specific Aortic Valve Implantation Guided by Software Using EncantoR

An interventional study of Transcatheter valve replacement therapy in Severe Native Calcific Aortic Stenosis and Symptomatic Heart Disease Due to Severe Native Calcific Aortic Stenosis, sponsored by Abbott Medical Devices. Not yet recruiting at 36 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Abbott Medical Devices (part of Abbott) · Not applicable, Interventional, and Treatment

How we know

Updated Nov 12, 2026First sites in 8 new countriesEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Aortic Valve Stenosis by Abbott — 4 open to participants now, 9 under way, none of them phase 3. Aortic Valve Stenosis · Abbott.

Planned enrollment
7th of 20
300 · median 177
Started
2026
the only one that year
No phase
19 of 26
2 open now
Registered
26th of 26
by date

Among the 26 studies in Aortic Valve Stenosis by Abbott, this one is the 7th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2026, is one of 19 with no phase, and was the 26th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

4 of the 26 studies in Aortic Valve Stenosis by Abbott are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Aortic Valve Stenosis by Abbott, or all of them as a file.
02

Study summary

VOYAGER CE Clinical Study using the Encantor TAVI System.

Read the detailed description

The VOYAGER CE trial is a prospective, single-arm, multi-center, pre-market clinical investigation designed to evaluate the safety and performance of the Encantor TAVI System. This clinical trial will enroll subjects who have symptomatic heart disease due to severe native calcific aortic stenosis and who are judged by a heart team to be appropriate for transcatheter valve replacement therapy.

03

Conditions studied

  • Severe Native Calcific Aortic Stenosis
  • Symptomatic Heart Disease Due to Severe Native Calcific Aortic Stenosis

Keywords

  • transcatheter valve replacement therapy
  • symptomatic heart disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject identified as appropriate for transcatheter heart valve intervention therapy for the treatment of symptomatic, severe aortic stenosis.
  • Subject is of legal age for consent (18 years old).
  • Willing to return for required follow-up visits and assessments

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing subjects.
  • Need for emergency surgery for any reason
  • Anatomic or comorbid conditions
  • Currently participating in an drug or device study that has not reached the primary endpoint or may confound the results of this trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Encantor TAVI System

    The Encantor System is intended to treat patients with symptomatic severe aortic stenosis via transcatheter aortic valve implantation (TAVI)

    Device: Transcatheter valve replacement therapy

Interventions

  • DeviceTranscatheter valve replacement therapy

    This intervention is distinguished by the use of the Encantor TAVI System, a transcatheter valve replacement therapy specifically designed for patients with symptomatic severe native calcific aortic stenosis who are considered appropriate candidates by a multidisciplinary heart team. This device is intended to provide a minimally invasive alternative to surgical aortic valve replacement.

06

What researchers measure

Primary outcomes

  1. Composite of all-cause mortality or all strokes at 12 months post index

    Composite of all-cause mortality or all strokes

    Time frame: 12 months post index

07

Study locations

36 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Sep 2028, 22 months later.

Of 111 industry-sponsored interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 54. This study's planned 22 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2026
First posted
Jul 10, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Sep 30, 2028
CompletionEst.
Dec 30, 2038
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
36 sites added — first sites in Australia, France, Germany, Italy, Norway and 3 more
All 8 countries

Australia, France, Germany, Italy, Norway, Portugal, Spain, Sweden

Show 36 added (11 Germany, 7 Australia, 6 France, 5 Italy, 3 Spain, 2 Sweden, 1 Norway, 1 Portugal)
  • The Prince Charles Hospital · Chermside, Australia
  • Monash Health · Clayton, Australia
  • The Alfred Hospital · Melbourne, Australia
  • Fiona Stanley Hospital · Murdoch, Australia
  • John Hunter Hospital · Newcastle, Australia
  • Macquarie University Hospital · Sydney, Australia
  • Royal Prince Alfred Hospital · Sydney, Australia
  • Hopital Haut Leveque · Bordeaux, France
  • Hopital d'adulte de la Timone · Marseille, France
  • Hôpital Saint Joseph · Marseille, France
  • Institute Cardio. Paris-Sud - Institut Jacques Cartier · Massy, France
  • CHRU Rouen Hospital Charles Nicolle · Rouen, France
  • Clinique Pasteur Toulouse · Toulouse, France
  • Kerckhoff-Klinik gGmbH · Bad Nauheim, Germany
  • Herz-und Diabetes Zentrum NRW · Bad Oeynhausen, Germany
  • Deutsches Herzzentrum der Charité · Berlin, Germany
  • Klinikum Dortmund gGmbH · Dortmund, Germany
  • St.-Johannes-Hospital · Dortmund, Germany
  • Herzzentrum Dresden GmbH Universitätsklinik · Dresden, Germany
  • Klinikum der Johann Wolfgang Goethe-Universität Frankfurt · Frankfurt, Germany
  • UKE Hamburg (Universitatsklinik Eppendorf) · Hamburg, Germany
  • Universitätsklinikum Schleswig-Holstein - Campus Kiel · Kiel, Germany
  • Herzzentrum Leipzig GmbH · Leipzig, Germany
  • TUM Klinikum - Deutsches Herzzentrum München · München, Germany
  • IRCCS AOU di Bologna Policlinico Sant'Orsola · Bologna, Italy
  • Pineta Grande Hospital · Castel Volturno, Italy
  • Centro Cardiologico Monzino · Milan, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, Italy
  • Policlinico San Donato · San Donato Milanese, Italy
  • Oslo University Hospital, Rikshospitalet · Oslo, Norway
  • …and 6 more on the registry record
Nov 12, 2026
Enrollment
150→300
Nov 12, 2026
Interventions
Changed Prospective, single-arm, multi-center study.→Transcatheter valve replacement therapy. Arms added: Encantor TAVI System; arms removed: Transcatheter valve replacement therapy
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    36 sites added — first sites in Australia, France, Germany, Italy, Norway and 3 more
    All 8 countries

    Australia, France, Germany, Italy, Norway, Portugal, Spain, Sweden

    Show 36 added (11 Germany, 7 Australia, 6 France, 5 Italy, 3 Spain, 2 Sweden, 1 Norway, 1 Portugal)
    • The Prince Charles Hospital · Chermside, Australia
    • Monash Health · Clayton, Australia
    • The Alfred Hospital · Melbourne, Australia
    • Fiona Stanley Hospital · Murdoch, Australia
    • John Hunter Hospital · Newcastle, Australia
    • Macquarie University Hospital · Sydney, Australia
    • Royal Prince Alfred Hospital · Sydney, Australia
    • Hopital Haut Leveque · Bordeaux, France
    • Hopital d'adulte de la Timone · Marseille, France
    • Hôpital Saint Joseph · Marseille, France
    • Institute Cardio. Paris-Sud - Institut Jacques Cartier · Massy, France
    • CHRU Rouen Hospital Charles Nicolle · Rouen, France
    • Clinique Pasteur Toulouse · Toulouse, France
    • Kerckhoff-Klinik gGmbH · Bad Nauheim, Germany
    • Herz-und Diabetes Zentrum NRW · Bad Oeynhausen, Germany
    • Deutsches Herzzentrum der Charité · Berlin, Germany
    • Klinikum Dortmund gGmbH · Dortmund, Germany
    • St.-Johannes-Hospital · Dortmund, Germany
    • Herzzentrum Dresden GmbH Universitätsklinik · Dresden, Germany
    • Klinikum der Johann Wolfgang Goethe-Universität Frankfurt · Frankfurt, Germany
    • UKE Hamburg (Universitatsklinik Eppendorf) · Hamburg, Germany
    • Universitätsklinikum Schleswig-Holstein - Campus Kiel · Kiel, Germany
    • Herzzentrum Leipzig GmbH · Leipzig, Germany
    • TUM Klinikum - Deutsches Herzzentrum München · München, Germany
    • IRCCS AOU di Bologna Policlinico Sant'Orsola · Bologna, Italy
    • Pineta Grande Hospital · Castel Volturno, Italy
    • Centro Cardiologico Monzino · Milan, Italy
    • Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, Italy
    • Policlinico San Donato · San Donato Milanese, Italy
    • Oslo University Hospital, Rikshospitalet · Oslo, Norway
    • …and 6 more on the registry record
    Enrollment 150→300
    Interventions Changed Prospective, single-arm, multi-center study.→Transcatheter valve replacement therapy. Arms added: Encantor TAVI System; arms removed: Transcatheter valve replacement therapy
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07696182
Responsible party
Sponsor
First posted
Jul 10, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Sep 30, 2028 (estimated)
Completion
Dec 30, 2038 (estimated)
Last update
Nov 12, 2026

Study contacts

Nadia Bouhdi
Contact
nadia.bouhdi@abbott.com
+32479941037
Lauren Harvey
Contact
lauren.harvey@abbott.com
Ashish Oza
study director · Abbott Structural Heart

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion